Head-to-head · free

Novartis vs AbCellera Biologics Inc.

A vs ABCL — return on capital, cash generation, margins and balance sheet side by side.

A

7 / 8

measures where A leads

ABCL

1 / 8

measures where ABCL leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureA · FY2025ABCL · FY2025
Revenue$6.9B$75.1M
Net income$1.3B(146.4M)
Revenue growth (yearly, multi-year)2.4%-33.1%
Free cash flow$1.2B(174.1M)
Free cash flow margin16.6%-231.7%
Net cash / (debt)——
ROIC13.9%—
Return on equity20.6%-14.5%
Gross margin52.4%—
Operating margin21.3%-270.5%
Net debt / EBITDA0.89x0.68x

Figures are as reported by each company; latest fiscal year shown.

Where Novartis's cash went (FY2025)

Capital spending
$407.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full A profile →

Where AbCellera Biologics Inc.'s cash went (FY2025)

Capital spending
$42.8M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ABCL profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons